MedTech Dive

CereVasc is developing a minimally invasive treatment for the buildup of fluid in the brain.

Keith Boettiger, head of Olympus’ gastrointestinal solutions division, delves into the endoscopy leader’s endoluminal robotics strategy.

In the lead-up to the American Diabetes Association’s Scientific Sessions, Dexcom announced an acquisition and Insulet improved the software for its latest patch pump.

Many adults are sharing device data with their providers too. But users are typically healthier and wealthier, suggesting people who could benefit the most from monitoring are less likely to adopt the tools, according to Rock Health.

Insulet, MiniMed and Tandem Diabetes Care are all working on systems to take meal announcements out of diabetes management.

Securing 510(k) authorization would position Medtronic to compete with Intuitive in major robotic surgery markets.

Built specifically to mimic the native tricuspid anatomy, the implant is intended to address an unmet patient need.

Strength in cardiac ablation solutions, where the company picked up market share, helped Medtronic post its best annual revenue growth rate in a decade.

In its first earnings call, the newly independent diabetes tech firm said it was transforming its product portfolio, with plans that include a patch pump and an algorithm that doesn’t require meal announcements.

A greater range of industrial and agricultural equipment made with the metals will temporarily face a reduced 15% levy starting June 8, per the White House.

Grail executives were upbeat on study results for the Galleri multi-cancer early detection test, while ASCO said more evidence is needed before it is incorporated into screening guidelines.

The buyout gives Resmed control of a noninvasive treatment for restless legs syndrome.

Patton’s promotion comes as competition in robotic surgery intensifies, and Intuitive looks to expand its global commercial operations to meet anticipated growth.

The U.S. appeals court ruled that Insulet filed the lawsuit too late, considering when it should have learned of the trade secret concerns.

The attorney general said the civil penalties could add up to “multiple millions” if the suit is successful.

The attorney general said the civil penalties could add up to “multiple millions” if the suit is successful.

Molecular residual disease testing could one day be as ubiquitous as a CT scan, says Natera’s president of clinical diagnostics.

Johnson & Johnson asked customers to quarantine and return affected products. A spokesperson said J&J conducted quality system audits as part of its integration of Abiomed that resulted in some field actions.

The new wellness tool would alert users to signs of increasing blood pressure. Ōura is studying a separate feature to flag hypertension that would go through the Food and Drug Administration.

Siemens Healthineers’ MRI scanners would guide robotic neurosurgeries performed with AiM’s platform. Elsewhere, Procept finished enrollment in a study of its aquablation treatment in prostate cancer.